Here is what nobody told you
And yet the stubborn fat remains
For reference, this is substantially higher than the equivalent human doses typically used
AOD-9604 Dosing Protocols Based on Clinical Research Dosing recommendations for AOD-9604 are based on extensive human research including six clinical trials that evaluated various administration routes, doses, and treatment durations
These include: Lifestyle interventions (dietary advice, physical activity programmes) Licensed pharmacotherapy such as orlistat, or GLP-1 receptor agonists including semaglutide 2.4 mg (Wegovy, NICE TA875) or tirzepatide (Zepbound) where clinically indicated and available Referral to tier 3 or tier 4 weight management services , including bariatric surgery assessment where appropriate Information on NHS weight management services and eligibility for licensed treatments is available via the NHS website and NICE guidance
A basic spreadsheet or notebook tracking: daily dose and time, weekly weight, bi-weekly measurements, and subjective notes provides sufficient data without excessive burden